Angel investor · Cambridge, United Kingdom
Recorded investments.
A clearer sense of fit.
Find where your company fits, how rounds are assembled, and what happened after the first investment.
of dated first investments
were at Angel, Pre-Seed or Seed
One dot = one company at first recorded investment.
Written insights from the recorded portfolio, with the evidence linked below.
Jonathan Milner has dated investments in 34 companies. 16 first entries were at Angel, Pre-Seed or Seed (47.1%). An early-stage founder can use the sector and stage filters to find comparable companies before approaching the investor.
Explore the evidence ↗6 first company relationships appear in the latest 24 months, compared with 2 in the preceding window. The latest recorded investment is 2025-12-02. This describes observed activity through 2026-05-22; it does not establish current availability.
Explore the evidence ↗11 of 28 companies with a full 24-month observation window raised another equity round. This investor backed 5 of those companies again within that window. The difference is a reason to research the wider syndicate, rather than assume the same investor will fund the next round.
Explore the evidence ↗Life Sciences is the largest displayed sector by company count, appearing in 30 portfolio companies; sector tags overlap. 5 first entries carry a recorded lead flag and the median first-round syndicate includes 4 other named backers. Shared rounds are evidence of co-investment, not evidence of an introduction route.
Explore the evidence ↗Start with observed behavior.
Every rate has a defined denominator.
25th–75th percentile across 33 disclosed first rounds. Total round size; the investor’s own cheque is undisclosed.
Size your round ↗22 May 2024–22 May 2026, versus 2 in the preceding 24 months.
See the rhythm ↗11 of 28 companies with a full observation window. The next round can include any investor.
Follow the path ↗5 of the same 28 companies. Build a financing plan around the wider investor market.
Explore co-investors ↗Choose your sector and stage to find
companies he first backed in that space.
A match means a recorded investment in this category. It does not establish current interest or availability.
All sectors · All entry stages. Round amounts are total financing, in USD.
Developer of medical imaging software for radiomics and biomarker analysis
$50M total first roundDeveloper of diagnostic and digital solutions for emergency care settings
$6.3M total first roundDeveloper of immunotherapeutics for the treatment of cancer
$31M total first round| Sector | Seed | Series A | Series B | All stages |
|---|---|---|---|---|
| Life Sciences | 30 | |||
| HealthTech | 13 | |||
| Life Sciences Tech | 9 | |||
| Biopharmaceuticals | 8 | |||
| Genomics | 8 | |||
| Life Sciences Platforms and Tools | 7 | |||
| Oncology | 6 |
Use stage-specific financing ranges
to frame the size of your syndicate.
Logarithmic scale. A dot marks the median; the band spans the 25th–75th percentiles. These are entire rounds, not individual cheques.
A subsequent round and repeat backing
answer different fundraising questions.
Includes first investments on or before 22 May 2024. 6 newer companies and 1 undated histories are excluded. Follow-up stops at the dataset’s latest round on 22 May 2026. These observations do not measure returns or predict a company’s outcome.
| First stage | Eligible companies | Next round ≤24 mo | Same investor again ≤24 mo |
|---|---|---|---|
| Seed | 13 | 5 / 13 | 1 / 13 |
| Series A | 12 | 5 / 12 | 3 / 12 |
| Series B | 3 | 1 / 3 | 1 / 3 |
Separate first investments from later
rounds in companies already backed.
*2026 is partial, through 22 May. Bar height counts first investments + repeat rounds; earlier years are complete calendar periods in this dataset.
Frequent shared rounds suggest a place
to investigate sector and stage alignment.
9 shared rounds · 5 companies
Latest shared round Sep 20248 shared rounds · 5 companies
Latest shared round Jan 20255 shared rounds · 4 companies
Latest shared round Aug 20234 shared rounds · 2 companies
Latest shared round Sep 20244 shared rounds · 3 companies
Latest shared round Oct 20244 shared rounds · 2 companies
Latest shared round May 2021Shared rounds establish recorded co-investment. They do not establish a personal connection, introduction route, or current willingness to invest.
First investment comes first.
Amounts refer to that entry round.
| Company | First backed | Entry stage | Total entry round | Same investor again? |
|---|---|---|---|---|
Quibim ↗Valencia | Jan 2025 | Series A | $50M | No later round recorded |
52 North Health ↗Cambridge | Nov 2024 | Series A | $6.3M | No later round recorded |
Epitopea ↗Cambridge | Oct 2024 | Seed | $31M | No later round recorded |
Shift Bioscience ↗Letchworth Garden City | Oct 2024 | Seed | $16M | No later round recorded |
Clock.bio ↗Cambridge | Oct 2024 | Seed | $5.3M | No later round recorded |
Constructive Bio ↗Saffron Walden | Sep 2024 | Series A | $58M | No later round recorded |
Relation ↗London | Jan 2024 | Seed | $40M | No later round recorded |
Spirea ↗Harrogate | Jun 2022 | Seed | $2.9M | No later round recorded |
Nuclera ↗Cambridge | Apr 2022 | Series B | $16M | Yes · Oct 2024 |
Axol Bioscience ↗Cambridge | Apr 2022 | Series A | $4.2M | No later round recorded |
Valence Labs ↗Montreal | Dec 2021 | Seed | $8.5M | No later round recorded |
SolasCure ↗Cambridge | Aug 2021 | Series A | $21M | Yes · Mar 2023 |
NanoSyrinx ↗Coventry | Jul 2021 | Seed | $8.5M | No later round recorded |
Clustermarket ↗London | Jun 2021 | Series A | $3.5M | No later round recorded |
Invizius ↗Edinburgh | May 2021 | Series A | $7.4M | No later round recorded |
Mogrify ↗Cambridge | May 2021 | Series A | $17M | Yes · Oct 2023 |
Pill Connect ↗Manchester | Nov 2020 | Seed | $658K | No later round recorded |
Psyomics ↗Cambridge | Oct 2020 | Series A | $2.0M | No later round recorded |
Totient ↗Cambridge | Sep 2020 | Seed | $10M | No later round recorded |
The Smarter Food Company ↗Norwich | Jul 2020 | Seed | $1.3M | No later round recorded |
Qkine ↗Cambridge | Apr 2020 | Series A | $1.9M | No later round recorded |
LIfT Biosciences ↗London | Jan 2020 | Seed | Undisclosed | Yes · Jan 2022 |
Pencil Biosciences ↗Alderley Edge | Dec 2019 | Seed | $658K | Yes · Aug 2023 |
Sense Biodetection ↗Abingdon | Oct 2019 | Series A | $13M | Yes · Oct 2020 |
Gelemetix ↗Macclesfield | Nov 2018 | Series B | $3.9M | No later round recorded |
Phoremost ↗Cambridge | May 2018 | Series A | $15M | Yes · Mar 2021 |
doppel ↗London | May 2018 | Seed | $1.9M | No later round recorded |
Repositive ↗Cambridge | Apr 2017 | Series A | $3.1M | No later round recorded |
Healx ↗Cambridge | Oct 2016 | Series A | $1.9M | Yes · Jul 2018 |
Gene Advisor ↗Cambridge | Jun 2016 | Seed | $506K | No later round recorded |
Desktop Genetics ↗London | Sep 2015 | Series A | $2.2M | No later round recorded |
GeoSpock ↗Cambridge | Nov 2014 | Seed | $1.3M | Yes · Oct 2015 |
Eagle Genomics ↗Cambridge | Sep 2013 | Seed | $918K | No later round recorded |
Horizon Discovery ↗Cambridge | Sep 2010 | Series B | $9.9M | Yes · Sep 2011 |
No companies match these filters. Try a broader sector or stage.
Kept in the 34-company portfolio; excluded from entry-timing calculations.
Search Cambridge, United Kingdom investor companies in Radar. Filter the company directory to explore the businesses behind your market and investor research.
Explore companies in Radar ↗We build customized research dashboards for companies. Tell us which competitors, markets and questions matter to your team, and discuss a dashboard designed around your needs.
Discuss a custom dashboard ↗A customized service from Fliar. Contact us to discuss your requirements.Use Fliar Prism to research a company, market or topic, with reports and insights drawn from its research dataset.
Explore Fliar Prism ↗Start with the company or question you want to understand.